As trials move forward, capturing tumor size and RECIST measurements consistently is critical for sponsors and regulators. Archer pulls data directly from source systems, preserving chain of custody and ensuring standardized, trusted information reaches regulators unchanged. This gives decision-makers confidence that trial outcomes truly reflect patient impact.